Profile data is unavailable for this security.
About the company
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
- Revenue in USD (TTM)4.69m
- Net income in USD-20.46m
- Incorporated2020
- Employees21.00
- LocationPetros Pharmaceuticals Inc1185 Avenue Of The Americas3Rd Floor, Suite 570NEW YORK 10036United StatesUSA
- Phone+1 (973) 242-0005
- Fax+1 (302) 655-5049
- Websitehttps://www.petrospharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals Inc | 22.36m | -1.14m | 2.67m | 37.00 | -- | -- | -- | 0.1196 | -0.1845 | -0.1845 | 0.7074 | -0.2648 | 2.40 | -- | 58.45 | 604,297.30 | -12.24 | -120.16 | -- | -678.29 | -- | -- | -5.11 | -1,559.63 | -- | -- | -- | -- | 101.37 | 29.16 | 34.43 | -- | -34.84 | -- |
| Aditxt Inc | 506.45k | -41.45m | 2.70m | 47.00 | -- | 0.2717 | -- | 5.33 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Sentient Brands Holdings Inc | 0.00 | -818.63k | 2.70m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Altamira Therapeutics Ltd | 118.49k | -8.17m | 2.71m | 10.00 | -- | 0.2464 | -- | 22.88 | -31.70 | -26.75 | 0.2412 | 4.91 | 0.0151 | 34.05 | 32.30 | 11,849.23 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 2.79m | 9.00 | -- | 0.3656 | -- | 0.2267 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Exicure Inc | 0.00 | -16.91m | 2.86m | 6.00 | -- | 0.9424 | -- | -- | -2.16 | -2.16 | 0.00 | 0.3504 | 0.00 | -- | -- | 0.00 | -96.91 | -41.52 | -109.98 | -55.78 | -- | -- | -- | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 2.89m | 24.00 | -- | -- | -- | 0.2031 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 2.91m | 21.00 | -- | 0.2922 | -- | 0.6197 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.57m | 2.93m | -- | -- | -- | -- | -- | -0.0188 | -0.0188 | 0.00 | -0.058 | 0.00 | -- | -- | -- | -390.77 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -6.05 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Livewire Ergogenics Inc | 67.98k | -1.09m | 2.98m | 1.00 | -- | -- | -- | 43.78 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 3.03m | 17.00 | -- | 51.03 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| DSwiss Inc | 1.68m | 144.71k | 3.12m | 11.00 | 21.57 | 13.30 | 15.97 | 1.86 | 0.0007 | 0.0007 | 0.0081 | 0.0011 | 4.43 | 189.17 | 35.95 | 152,321.80 | 38.27 | -8.69 | 79.40 | -45.47 | 32.65 | 25.55 | 8.64 | -2.47 | 2.04 | 66.93 | 0.1198 | -- | -20.50 | 46.20 | -688.36 | -- | -66.17 | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.13m | 40.00 | -- | 0.0847 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Onconetix Inc | 758.90k | -45.68m | 3.17m | 12.00 | -- | -- | -- | 4.17 | -2.41 | -2.41 | 0.0407 | 1.91 | 0.0156 | -- | 4.70 | 63,241.67 | -93.67 | -- | -137.89 | -- | -123.62 | -- | -6,019.45 | -- | 0.2752 | -17.12 | 0.2352 | -- | -- | -- | -176.78 | -- | -- | -- |
Data as of Jun 17 2024. Currency figures normalised to Petros Pharmaceuticals Inc's reporting currency: US Dollar USD
0.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 31.81k | 0.45% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 16.51k | 0.24% |
| Geode Capital Management LLCas of 31 Mar 2024 | 10.50k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 3.40k | 0.05% |
| EMFO LLCas of 31 Mar 2024 | 1.00k | 0.01% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 490.00 | 0.01% |
| National Bank Financial, Inc.as of 31 Mar 2024 | 313.00 | 0.00% |
| Newbridge Financial Services Group, Inc.as of 31 Mar 2024 | 120.00 | 0.00% |
| Group One Trading LPas of 31 Mar 2024 | 79.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 19.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
